Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 1/20 | 0.54 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | UQCRB | P14927 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957017 | 0.92 | SERPINE1 (0.54) | MAP2SERPINE1BRD4UQCRBALDH1A1 | |
| SCHEMBL13910226 | 0.91 | SERPINE1 (0.51) | MAP2SERPINE1BRD4UQCRBALDH1A1 | |
| SCHEMBL3955112 | 0.90 | MAP2 (0.60) | MAP2SERPINE1UQCRBCA1CA2 | |
| SCHEMBL3957351 | 0.87 | SERPINE1 (0.49) | MAP2SERPINE1BRD4UQCRBALDH1A1 | |
| SCHEMBL3957157 | 0.87 | HIF1A (0.52) | SERPINE1BRD4UQCRBALDH1A1MEN1 | |
| SCHEMBL4073082 | 0.86 | SERPINE1 (0.48) | SERPINE1BRD4UQCRBALDH1A1MEN1 | |
| SCHEMBL4144514 | 0.86 | ALDH1A1 (0.49) | SERPINE1BRD4UQCRBALDH1A1MEN1 | |
| SCHEMBL13906321 | 0.86 | SERPINE1 (0.48) | MAP2SERPINE1BRD4UQCRBALDH1A1 | |
| SCHEMBL3955450 | 0.85 | SERPINE1 (0.46) | MAP2SERPINE1BRD4UQCRBALDH1A1 | |
| SCHEMBL13906365 | 0.85 | SERPINE1 (0.47) | MAP2SERPINE1BRD4UQCRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | claimed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY5, ADCY2 | MAP2 3738/4885SERPINE1 2109/4885BRD4 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.